Mobile website
Clinical Research
Efficacy of mixed hematopoietic stem cell transplantation combined with donor lymphocyte infusion and IL-2 in treatment of acute myelogenous leukemia
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To study the efficacy of mixed-HSCT (autologous peripheral blood stem cell mixed with HLA haploidentical allogeneic bone marrow transplantation) combined with donor lymphocyte infusion plus interleukin-2 (DLI+IL-2) in treatment of acute myelogenous leukemia (AML) patients. Methods: Twenty-three AML patients (15 males and 8 females, median age 22 years) were enrolled in this study as mixed-HSCT combined DLI+IL-2 group, and 14 AML patients (10 males and 4 females, median age 21 years) were enrolled as control group. All patients in the two groups received TBI+VEMAC therapy after complete remission, patients in the control group were treated with mixed-HSCT alone, and those in the experimental group were treated with Mixed-HSCT and further treatment with DLI+IL-2 for 1-8 times after hematopoietic reconstruction. All the patients were followed up for at least 3 years. Results: All patients in the two groups achieved hematopoietic reconstruction and had no graft-versus-host disease (GVHD). During 3 years, 6 cases in the experimental group formed mixed chimerism (46XX/46XY) and 15 survived, with the disease-free survival rate (DFS) being 65.2%. Three cases in the control group formed mixed chimerism (46XX/46XY) and 7 cases survived, with the DFS being 50.0%. All patients in the two groups had similar adverse reactions (oral cavity ulcer, hemorrhagic cystitis, fever, etc.) after therapy. Conclusion: Mixed-HSCT combined with DLI+IL-2 has a positive effect on DFS of AML patients, with no noticeable adverse reactions.
Keywords:
Project Supported:
Project supported by the Outstanding Talents Foundation of PLA “11th Five-Year Plan” (No.06J005), and the Medical Research Foundation of Lanzhou Military Area Command of PLA (No.LXH-2007006)
Clc Number:
